In this study, we observed that a subtherapeutic dose (4 mg/kg) could be used to significantly decrease tumor hypoxia and modulate the tumor microenvironment in xenograft models of HER2+ breast cancer on day 7 and synergistically improves radiation therapy 14 days after the start of therapy (p < 0.05). Here, ERBB2 is linked to breast carcinoma.